Key Points
- SiBone director Jeffrey Dunn sold 3,575 shares on June 5 at an average price of $15.25, generating about $54,519. The sale reduced his holdings by 18.21% and was done to cover tax withholding tied to vesting equity awards.
- SiBone’s stock slipped 1.0% and opened at $14.97, leaving the company with a market cap of about $663.9 million. The stock remains well below its 52-week high of $21.89 but above its 52-week low of $11.48.
- Recent earnings beat expectations, with SiBone reporting a quarterly loss of $0.10 per share versus analysts’ estimate of a $0.17 loss. Revenue also topped forecasts at $52.59 million, while analysts currently rate the stock a “Moderate Buy” with a consensus target of $23.00.
SiBone (NASDAQ:SIBN - Get Free Report) Director Jeffrey Dunn sold 3,575 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $15.25, for a total value of $54,518.75. Following the sale, the director directly owned 16,057 shares in the company, valued at approximately $244,869.25. This trade represents a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
SiBone Stock Down 1.0%
SIBN stock opened at $14.97 on Tuesday. The company has a market cap of $663.92 million, a PE ratio of -38.38 and a beta of 0.70. The business has a 50-day simple moving average of $13.72 and a 200 day simple moving average of $15.91. SiBone has a 52 week low of $11.48 and a 52 week high of $21.89. The company has a quick ratio of 8.34, a current ratio of 9.99 and a debt-to-equity ratio of 0.20.
SiBone (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.07. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. The firm had revenue of $52.59 million for the quarter, compared to the consensus estimate of $51.16 million. Sell-side analysts anticipate that SiBone will post -0.44 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on SIBN. TD Cowen reduced their price target on shares of SiBone from $22.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, May 12th. Truist Financial restated a "buy" rating and set a $18.00 price objective (down from $20.00) on shares of SiBone in a research report on Tuesday, May 12th. Finally, Wall Street Zen downgraded SiBone from a "buy" rating to a "hold" rating in a report on Saturday, April 18th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.00.
Get Our Latest Report on SIBN
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. ANTIPODES PARTNERS Ltd bought a new stake in shares of SiBone during the 4th quarter valued at approximately $29,000. Royal Bank of Canada lifted its stake in SiBone by 98.5% in the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company's stock valued at $29,000 after purchasing an additional 736 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in SiBone by 64,700.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company's stock valued at $38,000 after purchasing an additional 1,941 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new stake in SiBone in the fourth quarter valued at approximately $53,000. Finally, State of Wyoming bought a new stake in shares of SiBone during the second quarter worth $55,000. Institutional investors own 98.11% of the company's stock.
About SiBone
(
Get Free Report)
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
